Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 23, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.

Zdravko Mitrovic1, Ivana Ilic, Marin Nola

  • 1Division of Hematology, Department of Medicine, University Hospital Center and Medical School University of Zagreb, Croatia. mitrovic@mef.hr

Clinical Lymphoma & Myeloma
|May 2, 2009
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

HemaSphere·2026
Same author

Early Metabolic and Oxidative Effects of Hop Extract, Alendronate, and Their Combination Across Tissues in an Estrogen-Deficient Rat Model: An Exploratory Study.

Nutrients·2026
Same author

CONCURRENT <i>CLOSTRIDIUM DIFFICILE</i> COLITIS AND CYTOMEGALOVIRUS INFECTION AS A CAUSE OF PERSISTENT DIARRHEA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMA FOLLOWING BENDAMUSTINE-BASED CONDITIONING.

Acta clinica Croatica·2026
Same author

Retrospective Analysis of Second Primary Malignancies in Patients with Mycosis Fungoides and Sézary Syndrome in Croatia.

Dermatology practical & conceptual·2025
Same author

Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe.

Cardio-oncology (London, England)·2025
Same author

Diagnostic and Therapeutic Challenges of Cutaneous Lymphoid Hyperplasia in the Facial Region: A Case Report.

Acta dermatovenerologica Croatica : ADC·2025

CD43 expression in diffuse large B-cell lymphoma (DLBCL) is an independent adverse prognostic factor. CD43-positive DLBCL patients show lower response and survival rates, especially with rituximab treatment.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • CD43 is a transmembrane glycoprotein found on various hematopoietic cells, including B lymphocytes.
  • Approximately 25% of diffuse large B-cell lymphomas (DLBCL) express CD43.
  • The prognostic value of CD43 expression in DLBCL was previously unknown.

Purpose of the Study:

  • To investigate the prognostic significance of CD43 expression in patients with newly diagnosed DLBCL.
  • To determine if CD43 expression impacts treatment response and survival outcomes.

Main Methods:

  • Immunohistochemical analysis of CD43 expression in 119 DLBCL patients.
  • Patients received CHOP-like chemotherapy, with or without rituximab.
  • Multivariate analysis and subgroup analyses were performed to assess prognostic impact.

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Related Experiment Videos

Last Updated: Jun 23, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
09:06

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma

Published on: November 11, 2021

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Main Results:

  • CD43 expression was observed in 26% of DLBCL cases.
  • CD43-positive DLBCL showed significantly lower complete response rates (59% vs. 80%) and poorer 2-year event-free survival (34% vs. 64%) and overall survival (45% vs. 76%).
  • CD43 expression remained an independent adverse prognostic factor in multivariate analysis (RR 2.04 for EFS, RR 2.17 for OS) and was significant in patients treated with rituximab and those with low IPI.

Conclusions:

  • CD43 expression is a significant independent adverse prognostic factor in DLBCL.
  • CD43 positivity is associated with inferior outcomes, particularly in rituximab-treated patients and those with low International Prognostic Index scores.